Senhwa Biosciences seeks US FDA nod for phase I/II study of Silmitasertib in combo with chemotherapy in children and ...
Senhwa Biosciences, Inc., announced IND Submission to US FDA for the phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumours. This investigator-initiated trial ( …